Generic drug savings by top drug in Canada's public drug plans 2012/2013

This statistic depicts total generic drug savings in Canadian public drug plans in 2012/2013, by top drug. The total savings for Nabilone (Cesamet) in selected Canadian public drug plans amounted to 11.06 million Canadian dollars.

Total generic drug savings in Canadian public drug plans in 2012/2013, by top drug (in million Canadian dollars)*

Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2015

Region

Canada

Survey time period

FY 2012/2013

Supplementary notes

* Total results are for top 5 entry drugs and only for select public drug plans included in this report.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.